The technology of in situ sequencing with RNA templated ligation is covered by patent no WO2019068880A1 and Cartana AB is the only company to provide the service.
While other technologies provide in situ detection of RNA species in tissues, the RNA templated ligation and in situ sequencing is the only one with specificity and multiplex capacity (41 targets) required for our purpose.
It is also crucial to get in situ sequencing with RNA templated ligation analysis as full service, including the design and production of customized probes, and this leaves Cartana AB as the only supplier on the market.